ABSTRACT:
We report a case of Candida glabrata candidemia that developed resistance to micafungin 19 within 8 days of starting therapy in a patient without previous echinocandin exposure or other known 20 risk factors for clinical or microbiological failure. Pre-and post-resistant isolates were confirmed to be 21 isogenic, and sequencing of hot spots known to confer echinocandin resistance revealed a phenylalanine 22 deletion at codon 659 within FKS2. 23 24 on July 7, 2017 by guest http://aac.asm.org/
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Echinocandins are now first line agents for the treatment of invasive candidiasis (1-4). Their fungicidal 25 activity, tolerability, perceived lack of resistance issues, and clinical superiority over fluconazole for 26 candidemia have made them a cornerstone of anti-Candida therapy (5). However, there are increasing 27 reports of Candida spp. becoming resistant to the echinocandins, usually in immunocompromised 28 patients receiving prolonged therapy (6, 7). In addition, there is debate over the recent changes to the 29 CLSI echinocandin breakpoints for Candida spp., which significantly lowered the threshold for resistance 30 for many species including C. glabrata (8). We describe a case of rapid emergence of echinocandin 31 resistance and clinical failure in a patient with C. glabrata fungemia who lacked the usual risk factors for 32 echinocandin resistance (6, 9, 10) . 33
Case. A female patient in her mid 50s presented to the emergency department with acute 34 pyelonephritis and persistent vomiting for the past 6 days. Her medical history was significant for a 35 cerebrovascular accident 5 years ago, poorly controlled type 2 diabetes, and hypertension. Blood and 36 urine cultures obtained in the emergency department grew E. coli that was resistant to ciprofloxacin and 37 trimethoprim-sulfamethoxazole. In the emergency department her blood glucose was >500mg/dL, she 38 was treated for an anion gap metabolic acidosis, and she received vancomycin and piperacillin-39 tazobactam. She improved initially but was transferred to the medical intensive care unit (MICU) due to 40 hypotension and respiratory failure requiring intubation. On hospital day 3, antibiotics were 41 deescalated to ceftriaxone when culture and susceptibility results returned. The patient developed 42 acute kidney injury that required dialysis through a left femoral vein catheter but otherwise experienced 43 a relatively uncomplicated ICU stay. On HD 11 she was transferred to the medical service, but on HD 13 44 she developed fever to 102. The C. glabrata isolates from HD13 prior to micafungin therapy (isolate CG1) and HD23 after 8 days of 71 therapy (CG2) were obtained from the clinical microbiology laboratory. Genomic DNA was extracted, 72 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from and random amplification of polymorphic DNA (RAPD) analysis was performed using previously 73 described primers (ERIC2, M13, OPE18, and OPA18) (11) (12) (13) (14) . RAPD profiles were compared with each 74 other and against genomic DNA extracted from a control isolate (C. glabrata ATCC 2001) on 1.2% w/v 75 agarose gels visualized with UV light following ethidium bromide staining. As shown in Figure 1 , RAPD 76 analysis strongly suggested strain isogenecity for isolates CG1 and CG2. 77
To identify mutations within conserved regions of genes encoding subunits of the glucan synthase 78 enzyme complex known to confer echinocandin resistance, hot spot regions in Candida glabrata FKS1 79 and FKS2 (GenBank accession no. XM-446406 and XM-448401) were amplified by PCR and purified (10, 80 15). The purified PCR product was then sequenced at the UTHSCSA Advanced Nucleic Acids Core facility 81 using Big Dye Terminator Cycle sequencing (Applied Biosystems, Inc., Foster City, CA) and analyzed with 82 an ABI Prism 3100 genetic analyzer. Sequences were aligned using the MacVector software package 83 (MacVector, Inc., Cary, NC) and compared to the control sequence (C. glabrata CBS138). The FKS1 hot 84 spot 1 showed a single silent point mutation from the control strain. In CG2, the hot spot 1 and hot spot 85 2 regions of FKS2 both had base pair differences that also resulted in silent mutations. However, a three 86 base pair deletion was also detected in hot spot 2 of FKS2 resulting in a single amino acid deletion 87 (F659del) that did not further change the reading frame (Figure 2 
